Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)
Status:
Not yet recruiting
Trial end date:
2022-06-13
Target enrollment:
Participant gender:
Summary
The primary purpose of this randomized, double-blind, placebo-controlled cross-over study is
to record and measure 40 Hz-auditory steady-state response (ASSR) in healthy controls (HC)
and participants with mild-to-moderate schizophrenia (SZ) to determine if the mean
inter-trial coherence (ITC) magnitude derived from the 40 Hz-ASSR is lower in SZ than in HC
at baseline.